Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 14 December 2001:
Vol. 294. no. 5550, pp. 2368 - 2371
DOI: 10.1126/science.1065806
Prev | Table of Contents | Next

Reports

Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy

Robert Pawliuk,12 Karen A. Westerman,12 Mary E. Fabry,3 Emmanuel Payen,4 Robert Tighe,12 Eric E. Bouhassira,3 Seetharama A. Acharya,3 James Ellis,5 Irving M. London,16 Connie J. Eaves,7 R. Keith Humphries,7 Yves Beuzard,4 Ronald L. Nagel,3 Philippe Leboulch1248*

Sickle cell disease (SCD) is caused by a single point mutation in the human beta A globin gene that results in the formation of an abnormal hemoglobin [HbS (alpha 2beta S2)]. We designed a beta A globin gene variant that prevents HbS polymerization and introduced it into a lentiviral vector we optimized for transfer to hematopoietic stem cells and gene expression in the adult red blood cell lineage. Long-term expression (up to 10 months) was achieved, without preselection, in all transplanted mice with erythroid-specific accumulation of the antisickling protein in up to 52% of total hemoglobin and 99% of circulating red blood cells. In two mouse SCD models, Berkeley and SAD, inhibition of red blood cell dehydration and sickling was achieved with correction of hematological parameters, splenomegaly, and prevention of the characteristic urine concentration defect.

1 Harvard-MIT, Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
2 Genetix Pharmaceuticals, Cambridge, MA 02139, USA.
3 Division of Hematology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4 INSERM EMI 0111, Hôpital Saint-Louis, 75010 Paris, France.
5 Department of Genetics, Hospital for Sick Children, Toronto, ON M5G1X8, Canada.
6 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
7 The Terry Fox Laboratory and the University of British Columbia, Vancouver, BC V5Z3L6, Canada.
8 Harvard Medical School and Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115 USA.
*   To whom correspondence should be addressed. E-mail: pleboulch{at}mit.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.
A. Perumbeti, T. Higashimoto, F. Urbinati, R. Franco, H. J. Meiselman, D. Witte, and P. Malik (2009)
Blood 114, 1174-1185
   Abstract »    Full Text »    PDF »
Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.
L. Ye, J. C. Chang, C. Lin, X. Sun, J. Yu, and Y. W. Kan (2009)
PNAS 106, 9826-9830
   Abstract »    Full Text »    PDF »
Amelioration of murine {beta}-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both {gamma}-globin and the MGMT drug-resistance gene.
H. Zhao, T. I. Pestina, M. Nasimuzzaman, P. Mehta, P. W. Hargrove, and D. A. Persons (2009)
Blood 113, 5747-5756
   Abstract »    Full Text »    PDF »
The Core Element of a CpG Island Protects Avian Sarcoma and Leukosis Virus-Derived Vectors from Transcriptional Silencing.
F. Senigl, J. Plachy, and J. Hejnar (2008)
J. Virol. 82, 7818-7827
   Abstract »    Full Text »    PDF »
In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of {beta}-thalassemia.
A. Miccio, R. Cesari, F. Lotti, C. Rossi, F. Sanvito, M. Ponzoni, S. J. E. Routledge, C.-M. Chow, M. N. Antoniou, and G. Ferrari (2008)
PNAS 105, 10547-10552
   Abstract »    Full Text »    PDF »
Development of gene therapy for blood disorders.
A. W. Nienhuis (2008)
Blood 111, 4431-4444
   Abstract »    Full Text »    PDF »
Towards the genetic treatment of {beta}-thalassemia: new disease models, new vectors, new cells.
P. Moi and M. Sadelain (2008)
Haematologica 93, 325-330
   Full Text »    PDF »
Gene Replacement Therapy for Sickle Cell Disease and Other Blood Disorders.
T. M. Townes (2008)
Hematology 2008, 193-196
   Abstract »    Full Text »    PDF »
Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin.
J. Hanna, M. Wernig, S. Markoulaki, C.-W. Sun, A. Meissner, J. P. Cassady, C. Beard, T. Brambrink, L.-C. Wu, T. M. Townes, et al. (2007)
Science 318, 1920-1923
   Abstract »    Full Text »    PDF »
Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in -thalassemic mice.
L. Lisowski and M. Sadelain (2007)
Blood 110, 4175-4178
   Abstract »    Full Text »    PDF »
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.
F. Bernaudin, G. Socie, M. Kuentz, S. Chevret, M. Duval, Y. Bertrand, J.-P. Vannier, K. Yakouben, I. Thuret, P. Bordigoni, et al. (2007)
Blood 110, 2749-2756
   Abstract »    Full Text »    PDF »
Fetal gene therapy of {alpha}-thalassemia in a mouse model.
X.-D. Han, C. Lin, J. Chang, M. Sadelain, and Y. W. Kan (2007)
PNAS 104, 9007-9011
   Abstract »    Full Text »    PDF »
HIF-dependent induction of adenosine A2B receptor in hypoxia.
T. Kong, K. A. Westerman, M. Faigle, H. K. Eltzschig, and S. P. Colgan (2006)
FASEB J 20, 2242-2250
   Abstract »    Full Text »    PDF »
Correction of sickle cell disease by homologous recombination in embryonic stem cells.
L.-C. Wu, C.-W. Sun, T. M. Ryan, K. M. Pawlik, J. Ren, and T. M. Townes (2006)
Blood 108, 1183-1188
   Abstract »    Full Text »    PDF »
Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism.
D. M. Dykxhoorn, L. D. Schlehuber, I. M. London, and J. Lieberman (2006)
PNAS 103, 5953-5958
   Abstract »    Full Text »    PDF »
Survival of the fittest: in vivo selection and stem cell gene therapy.
T. Neff, B. C. Beard, and H.-P. Kiem (2006)
Blood 107, 1751-1760
   Abstract »    Full Text »    PDF »
HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia.
H. K. Eltzschig, P. Abdulla, E. Hoffman, K. E. Hamilton, D. Daniels, C. Schonfeld, M. Loffler, G. Reyes, M. Duszenko, J. Karhausen, et al. (2005)
J. Exp. Med. 202, 1493-1505
   Abstract »    Full Text »    PDF »
Dynamic DNA Methylation and Histone Modifications Contribute to Lentiviral Transgene Silencing in Murine Embryonic Carcinoma Cells.
J. He, Q. Yang, and L.-J. Chang (2005)
J. Virol. 79, 13497-13508
   Abstract »    Full Text »    PDF »
Differences of globin transgene expression in stably transfected cell lines and transgenic mice.
Q. Li, D. W. Emery, H. Han, J. Sun, M. Yu, and G. Stamatoyannopoulos (2005)
Blood 105, 3346-3352
   Abstract »    Full Text »    PDF »
Stem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy.
M. C. Walters (2005)
Hematology 2005, 66-73
   Abstract »    Full Text »    PDF »
One step closer to gene therapy for hemoglobinopathies.
B. P. Sorrentino (2004)
Blood 104, 3419
   Full Text »    PDF »
Successful correction of the human {beta}-thalassemia major phenotype using a lentiviral vector.
G. Puthenveetil, J. Scholes, D. Carbonell, N. Qureshi, P. Xia, L. Zeng, S. Li, Y. Yu, A. L Hiti, J.-K. Yee, et al. (2004)
Blood 104, 3445-3453
   Abstract »    Full Text »    PDF »
Locus control region elements HS2 and HS3 in combination with chromatin boundaries confer high-level expression of a human {beta}-globin transgene in a centromeric region.
S.-H. L. Kang, P. P Levings, F. Andersen, P. J Laipis, K. I Berns, R. T Zori, and J. Bungert (2004)
Genes Cells 9, 1043-1053
   Abstract »    Full Text »    PDF »
Extended {beta}-globin locus control region elements promote consistent therapeutic expression of a {gamma}-globin lentiviral vector in murine {beta}-thalassemia.
H. Hanawa, P. W. Hargrove, S. Kepes, D. K. Srivastava, A. W. Nienhuis, and D. A. Persons (2004)
Blood 104, 2281-2290
   Abstract »    Full Text »    PDF »
Identification of Synthetic Endothelial Cell-Specific Promoters by Use of a High-Throughput Screen.
C. Dai, R. E. McAninch, and R. E. Sutton (2004)
J. Virol. 78, 6209-6221
   Abstract »    Full Text »    PDF »
Personalized Medicine.
J. H. Thrall (2004)
Radiology 231, 613-616
   Full Text »    PDF »
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.
H. Hanawa, P. Hematti, K. Keyvanfar, M. E. Metzger, A. Krouse, R. E. Donahue, S. Kepes, J. Gray, C. E. Dunbar, D. A. Persons, et al. (2004)
Blood 103, 4062-4069
   Abstract »    Full Text »    PDF »
Lentiviral vector for hemophilia gene therapy.
R. W. Herzog (2004)
Blood 103, 3609-3610
   Full Text »    PDF »
Deletion of a Negatively Acting Sequence in a Chimeric GATA-1 Enhancer-Long Terminal Repeat Greatly Increases Retrovirally Mediated Erythroid Expression.
A. Testa, F. Lotti, L. Cairns, A. Grande, S. Ottolenghi, G. Ferrari, and A. Ronchi (2004)
J. Biol. Chem. 279, 10523-10531
   Abstract »    Full Text »    PDF »
Gene therapy for sickle cell disease marches on.
D. M. Bodine (2003)
Blood 102, 4247
   Full Text »    PDF »
Correction of a mouse model of sickle cell disease: lentiviral/antisickling {beta}-globin gene transduction of unmobilized, purified hematopoietic stem cells.
D. N. Levasseur, T. M. Ryan, K. M. Pawlik, and T. M. Townes (2003)
Blood 102, 4312-4319
   Abstract »    Full Text »    PDF »
Plasticity of marrow-derived stem cells.
E. L. Herzog, L. Chai, and D. S. Krause (2003)
Blood 102, 3483-3493
   Abstract »    Full Text »    PDF »
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation.
L. de Franceschi, A. Baron, A. Scarpa, C. Adrie, A. Janin, S. Barbi, J. Kister, P. Rouyer-Fessard, R. Corrocher, P. Leboulch, et al. (2003)
Blood 102, 1087-1096
   Abstract »    Full Text »    PDF »
Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
D. A. Persons, E. R. Allay, N. Sawai, P. W. Hargrove, T. P. Brent, H. Hanawa, A. W. Nienhuis, and B. P. Sorrentino (2003)
Blood 102, 506-513
   Abstract »    Full Text »    PDF »
Performance- and safety-enhanced lentiviral vectors containing the human interferon-{beta} scaffold attachment region and the chicken {beta}-globin insulator.
A. Ramezani, T. S. Hawley, and R. G. Hawley (2003)
Blood 101, 4717-4724
   Abstract »    Full Text »    PDF »
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta -globin gene transfer.
S. Rivella, C. May, A. Chadburn, I. Riviere, and M. Sadelain (2003)
Blood 101, 2932-2939
   Abstract »    Full Text »    PDF »
Side effects of retroviral gene transfer into hematopoietic stem cells.
C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle (2003)
Blood 101, 2099-2113
   Abstract »    Full Text »    PDF »
The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma -globin gene is influenced by chromosomal position effects and vector copy number.
D. A. Persons, P. W. Hargrove, E. R. Allay, H. Hanawa, and A. W. Nienhuis (2003)
Blood 101, 2175-2183
   Abstract »    Full Text »    PDF »
ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
J. W. Stocker, L. De Franceschi, G. A. McNaughton-Smith, R. Corrocher, Y. Beuzard, and C. Brugnara (2003)
Blood 101, 2412-2418
   Abstract »    Full Text »    PDF »
LCR-regulated transgene expression levels depend on the Oct-1 site in the AT-rich region of beta -globin intron-2.
R. R. Bharadwaj, C. D. Trainor, P. Pasceri, and J. Ellis (2003)
Blood 101, 1603-1610
   Abstract »    Full Text »    PDF »
Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector.
P. J. Gough and E. W. Raines (2003)
Blood 101, 485-491
   Abstract »    Full Text »    PDF »
Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
S. Imren, E. Payen, K. A. Westerman, R. Pawliuk, M. E. Fabry, C. J. Eaves, B. Cavilla, L. D. Wadsworth, Y. Beuzard, E. E. Bouhassira, et al. (2002)
PNAS 99, 14380-14385
   Abstract »    Full Text »    PDF »
Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma -globin gene silencing in vivo.
D. W. Emery, E. Yannaki, J. Tubb, T. Nishino, Q. Li, and G. Stamatoyannopoulos (2002)
Blood 100, 2012-2019
   Abstract »    Full Text »    PDF »
Pharmacologically regulated in vivo selection in a large animal.
T. Neff, P. A. Horn, V. E. Valli, A. M. Gown, S. Wardwell, B. L. Wood, C. von Kalle, M. Schmidt, L. J. Peterson, J. C. Morris, et al. (2002)
Blood 100, 2026-2031
   Abstract »    Full Text »    PDF »
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
B. D. Brown and D. Lillicrap (2002)
Blood 100, 1133-1140
   Abstract »    Full Text »    PDF »
Expression of a human beta -globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells.
F. E. Nicolini, S. Imren, I.-H. Oh, R. K. Humphries, P. Leboulch, M. E. Fabry, R. L. Nagel, and C. J. Eaves (2002)
Blood 100, 1257-1264
   Abstract »    Full Text »    PDF »
Gene Therapy Corrects Sickle Cell Disease in Mice.
(2001)
Journal Watch (General) 2001, 4
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)